Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


German diagnostics set to lose pillar of strength

This article was originally published in Clinica

Executive Summary

The roof over the in vitro diagnostics industry in Germany will stay up, albeit without one of its main pillars: Dierk Meyer-Luerssen will leave the national diagnostics industry association, the VDGH, of which he has been key component for 31 years, in 2009. The industry will be hoping that Mr Meyer-Luerssen's successor will be able to match his technical insight, knowledge and general ability to "convey the message" for an industry that has grown from E100m in 1977 to almost E2bn ($3.12bn) today - E2.2bn including non-VDGH adherents. That message has always been of vital nature of early diagnosis and optimum use of IVDs and of the importance of reimbursement for new tests. The VDGH director, who will be succeeded by association director Dr Martin Walger, has consistently been an energetic proponent of fair treatment for an industry that has to struggle - however inconceivable that may be - for attention and funding, in Germany as elsewhere. Clinica, among others, will miss his clarity and ability to convey messages about complex technologies in a clear - and often forthright -manner. See this issue, page 23.

You may also be interested in...

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims

Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts